30 May 2025
30 May 2025
Researchers used ArteraAI to identify 25% of prostate cancer patients in a large trial cohort for whom abiraterone halved the risk of death.
The authorisation for the histotripsy system was granted under the UK’s Innovative Devices Access Pathway (IDAP).
This expansion of the laser product line aims to enhance accessibility for providers and their patients.
The randomised controlled trial is currently enrolling at approximately ten sites across the US.
The tests add to the company’s existing PGx offerings for blood clotting, mental health, and immune suppression treatments.
Illumina’s TSO Comprehensive IVD test and two companion diagnostic (CDx) indications secured approval from the FDA last year.
This surge in growth may be less about increased patient demand and more about precautionary stockpiling.
The system has been leveraged in 2,000 procedures across over 30 types of surgical procedures.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
